Evercore ISI lowered the firm’s price target on Edwards Lifesciences to $70 from $76 and keeps an In Line rating on the shares. In MedTech, utilization remains positive into Q3 and the capex outlook into the next year remains “healthy,” says Evercore. In life science tools, bioprocess trends for are on track for improvement in the second half, but the debate is around the instrument outlook and China stimulus given the recent run in stocks in the space, the analyst tells investors in MedTech and Tools Q3 preview.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences price target lowered to $77 from $83 at Citi
- Eyes on Fed ahead of expected interest rate cut: Morning Buzz
- Nvidia, ARM initiated: Wall Street’s top analyst calls
- Edwards Lifesciences downgraded to Hold from Buy at Jefferies
- Edwards Lifesciences rumor highlighted in Betaville blog